SEV-ERAL authors have described how measurements of cell surviving fraction following bleomycin (BLM) treatment of a solid mouse tumour Twentyman and Bleehen, 1974, 1975) or a mouse ascites tumour (Takabe et al., 1974) are extremelv dependent upon the time after treatment at which the assay is performed. Suirviving fractions measured within 2 h of drug treatment are much lower than those observed following a delay of 6-24 h. The experiments described here indicate that an artefact is involved and that surviving fractions measured soon after BLM treatment are likely to be falsely low.
The EMT6 tumour and the method of handling as used in our laboratory have been previously described (Rockwell, Kallman & Farjardo, 1972; Twentyman and Bleehen, 1974, 1975 Table I . In each case, the cell yield from the treated and untreated tumour halves was similar, hence in the third suspension (0) half of the total number of cells would have come from each of the 2 tumour halves. It is seen that, in each experiment, the number of colonies produced by Suspension 0 was much lower than would have been expected from the colony-forming ability of the individual halves. If, however, cells from the 2 separate suspensions ( -and + )
were plated into the same dish, no interaction was seen, and the colony count was merely the sum of the counts produced by the individual suspensions. These experiments were repeated with (a) the omission of trypsin from the Hanks' solution and (b) using complete medium instead of trypsinized Hanks' solution for making the suspensions. In both these cases, there was considerably more cell debris present in the suspensions produced, and the plating efficiencies were lower. The results, however, were in each case very similar to those shown in Table I .
Experiments combining tumour halves in which the treated tumour had received either X-rays, cyclophosphamide or BCNU are shown in Table II . In each of these experiments, and in similar repeats, there was no interaction between the colony formation of the tumour halves as has been described for BLM.
DISCUSSION
The results presented here show that, for BLM, but not for any of the other agents studied, drug carry-over presents a problem in measuring surviving fraction at early times after drug administration in vivo. Drug carried over by tumours from BLM-treated animals into the suspension vessel is able to kill cells from untreated tumours in the same vessel. There is no reason to think that cells from the tumour which did the carrying-over are not killed to at least the same extent as are cells from the untreated tumour.
In the light of these results, it would appear that the observed rapid change in measured surviving fraction following BLM treatment in vivo of the EMT6 tumour Twentyman and Bleehen, 1974, 1975) can be explained without recourse to the phenomenon of ''recovery from potentially lethal damage". However, in other circumstances where an unexplained change in measured surviving fraction occurs (i.e. following X-irradiation (Little et al., 1973) , cyclophosphamide Twentyman, 1977) , or BCNU (Twentyman, in preparation), the artefact described here does not appear to operate.
